A Look At Payers' Early Game Plans For Driving Biosimilar Use

Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.

US payers have a number of mechanisms in their policy toolbox that they can use to steer drug use toward the wave of biosimilars coming on the market – most importantly, prior authorization and requiring that patients try a biologic copy before a branded drug.

As the US has trailed behind Europe in developing a system for approving biologic copies, not to mention lawsuits that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Biosimilars & Generics